IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

ICANT: **GROUP ART UNIT:** Yatin Gokarn

1632

SERIAL NO.:

10/721,645

CONFIRMATION NO.:

7427

EXAMINER:

Unknown

ATTORNEY DOCKET

3598/1

FILED:

11/25/03

NO.:

TITLE:

Concentrated Liquid Valdecoxib Composition

July 12, 2004

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97 and 1.98

Commissioner of Patents Box 1450 Alexandria, VA 22313

Sir:

This Information Disclosure Statement is filed pursuant to 37 CFR 1.97 and 1.98 and MPEP §609. Copies of the references listed on the attached Form PTO-1449 are enclosed herein.

Each item contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. No fee is required under §1.97.

Respectfully submitted,

Patricia K. Fitzsimmons Attorney for Applicants Registration No. 52,894

(314) 274-1490

Pharmacia Corporation of Pfizer Inc. Global Patent Department Post Office Box 1027

OIPE			
JUL 1 5 2004 E	TRANSMITTAL LETTER (General - Patent Pending)		Docket No. 3598/1
In Fig. Application Of: Y	atin Gokarn		
Serial No.	Filing Date	Examiner	Group Art Unit
10/721,645 Title: Concentrated Liq	11/25/03	Unknown	1632
Title: Concentrated Liquid Valdecoxib Composition TO THE COMMISSIONER FOR PATENTS:			
Transmitted herewith is: Transmittal Letter, IDS	Statement, IDS Form 1449, Copie	es of References, and Return Postca	rd
in the above identified ap			
No additional fee is required. A check in the amount of is attached. The Director is hereby authorized to charge and credit Deposit Account No. as described below. Charge the amount of Credit any overpayment. Charge any additional fee required.			
Patricial	Thrium gnatule	Dated: July 12, 2004	

Patricia K. Fitzsimmons 52,894

I certify that this document and fee is being deposited on 7/12/04 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Signature of Person Mailing Corpspondence

Linda Haley

Typed or Printed Name of Person Mailing Correspondence

ORM PTO-1449

U.S. DEPARTMENT OF
COMMERCE, PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

	511000 1 01 2
ATTY. DOCKET NO: 3598/1	APPLICATION NO.: 10/721,645
INVENTOR: Yatin Gokarn	
Filed: 11/25/03	Group: 1632

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	A1	2002/0128267 A1	9/12/02	Bandyopadhyay			
	 						
	-						
-	 						
-	+						
	+						·

FOREIGN PATENT DOCUMENTS

Examiner							Transla	ition
Initial		Document Number	Date	Country	Class	Subclass	Yes	No
	B1	WO 02/05815 A1	1/24/02	WO			X	
	<u> </u>							
	ļ							
	<u> </u>							

EXAMINER	DATE CONSIDERED	
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609.		
Draw line through citation if not in conformance and not considered. Include copy of this form with		
next communication to applicant.		



Sheet 2 of 2

FORM PTO-1449 COMMERCE, PATENT A	U.S. DEPARTMENT OF ND TRADEMARK OFFICE	ATTY. DOCKET NO.: 3598/1	APPLICATION NO.: 10/721,645
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		INVENTOR: Yatin Gokarn	
(Use several sh	eets if necessary)	Filed: 11/25/03	Group: 1632

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
	C1	Rawat, et. al., Rofecoxib-β-Cyclodextrin Inclusion Complex for Solubility Enhancement, Die Pharmazie, Germany, Vol. 58, No. 9 (2003) 639-641
	C2	International Search Report, PCT/US 03/36244 (5/28/04)
· · · · · · · · · · · · · · · · · · ·		
	<u> </u>	
	1	
	+	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether Draw line through citation if not in conformance a next communication to applicant.	or or not citation is in conformance with MPEP 609. Ind not considered. Include copy of this form with

(Form PTO-1449)